ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 41 filers reported holding ADC THERAPEUTICS SA in Q3 2023. The put-call ratio across all filers is 2.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,606,431 | -61.9% | 2,905,721 | -8.7% | 0.00% | 0.0% |
| Q2 2023 | $6,839,685 | +3.8% | 3,181,249 | -5.9% | 0.00% | 0.0% |
| Q1 2023 | $6,589,448 | -14.3% | 3,379,204 | +68.8% | 0.00% | -50.0% |
| Q4 2022 | $7,685,253 | +3062.7% | 2,001,368 | +3879.6% | 0.00% | – |
| Q3 2022 | $243,000 | -11.6% | 50,291 | +45.3% | 0.00% | – |
| Q2 2022 | $275,000 | -39.6% | 34,600 | +11.6% | 0.00% | – |
| Q1 2022 | $455,000 | +3.4% | 31,000 | +42.2% | 0.00% | – |
| Q4 2021 | $440,000 | -16.2% | 21,800 | +12.7% | 0.00% | – |
| Q3 2021 | $525,000 | -67.5% | 19,346 | -70.8% | 0.00% | – |
| Q2 2021 | $1,614,000 | +30.0% | 66,299 | +30.4% | 0.00% | – |
| Q1 2021 | $1,242,000 | -57.8% | 50,862 | -44.7% | 0.00% | -100.0% |
| Q4 2020 | $2,944,000 | +111.5% | 91,998 | +209.4% | 0.00% | – |
| Q2 2020 | $1,392,000 | – | 29,738 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,186,215 | $4,555,066 | 2.69% |
| Blue Owl Capital Holdings LP | 733,568 | $2,816,901 | 1.20% |
| Redmile Group, LLC | 7,590,849 | $29,148,860 | 1.19% |
| AlphaCentric Advisors LLC | 297,500 | $1,142,400 | 1.13% |
| Prosight Management, LP | 463,310 | $1,779,110 | 0.97% |
| GCM Grosvenor Holdings, LLC | 735,471 | $2,824,209 | 0.72% |
| Indie Asset Partners, LLC | 93,839 | $360,342 | 0.40% |
| XTX Topco Ltd | 197,635 | $758,918 | 0.16% |
| Eventide Asset Management | 1,879,959 | $7,219,043 | 0.14% |
| Nantahala Capital Management | 243,290 | $934,234 | 0.06% |